Tiazac Articles
China Sky One has 11 generics in pipeline
21 July 2008
KV's fiscal 3rd-qtr net revenue jumps 39%
17 March 2008
Andrx' 4th-qtr 2005 income drops 16%
27 March 2006
Biovail launches Tiazac XC in Canada
31 January 2005
KV resolves a handful of legal matters
20 September 2004
Biovail's Tiazac XC cleared in Canada
23 August 2004
B-MS settles US FTC/states
17 March 2003
B-MS settles US FTC/states
17 March 2003
Biovail closer to Cardizem XL launch
24 June 2002
US business, govs seek Hatch-Waxman reform
13 May 2002
US FTC probes Orange Book patent listings
14 January 2002
Lower earnings expected at Andrx
14 January 2002
Forest to sell Sankyo's Benicar
13 December 2001
FDA slammed over Rx "applesauce" data
20 November 2001
US consumer groups demand Tiazac patent withdrawal
22 August 2001
US House votes more support for generics
27 July 2001
Recordati licenses lercanidipine to Forest in USA
8 November 2000
Biovail once-daily diltiazem cleared
8 March 2000
Andrx Submits ANDA For Bioequivalent Drugs
23 September 1998
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
FDA Approves Biovail's Tiazac
5 February 1998
Biovail Earnings Boosted By Tiazac
7 August 1997
Biovail Launches Tiazac In Canada
21 April 1997
Fears Over Tiazac Hit Biovail
23 December 1996
Further Profits Warnings From Forest Labs
9 December 1996
Biovail Shares Soar On Firm's Good News
9 December 1996
US Corporate Results Round-Up
27 May 1996
Extended-Release Diltiazem Available
19 February 1996
Transition For AHP in 1995; Year-End Results
5 February 1996
Galephar-Tiazac/ Biovail Deal Clarified
9 October 1995
Biovail acquires Galephar
25 September 1995
Hoechst Marion Roussel Begins To Take Shape
25 September 1995
Wille Labs Secures Generics deal
12 December 1994
Tanabe Reports Revenue Decline
5 December 1994
US PRESCRIBING TRENDS IN MARCH
28 June 1993
TANABE PROFITS UP IN FISCAL 92/93
14 June 1993
Showing 1-44 of 44 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
